{"schema_version":"secwatch.filing_event.v1","accession":"0000927066-23-000207","form_type":"8-K","ticker":"DVA","cik":"0000927066","company_name":"DAVITA INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.439614+00:00","generated_at":"2026-06-08T18:41:42.089585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DaVita Q3 2023 adjusted EPS $2.85, revenue $3.1B, operating cash flow $661M","bullets":["GAAP diluted EPS $2.62; adjusted diluted EPS $2.85, up from $2.08 in Q2 2023.","Consolidated revenue $3.1 billion; operating income $496M, adjusted operating income $525M.","Operating cash flow $661M; free cash flow $453M for the quarter.","Nine-month 2023 net income $541M vs $492M in prior year; diluted EPS $5.80 vs $5.07.","CEO Javier Rodriguez cited continued momentum and focus on operating discipline and patient care."],"urls":{"canonical":"https://secwatch.observer/filing/0000927066-23-000207","json":"https://secwatch.observer/filing/0000927066-23-000207.json","markdown":"https://secwatch.observer/filing/0000927066-23-000207.md","text":"https://secwatch.observer/filing/0000927066-23-000207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000207/0000927066-23-000207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000207/dva-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:41:42.089585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50eaf8ab98e23ae5c91de14242e2aaf509da3f36","claim":"DAVITA INC. reported the quarter ended September 30, 2023 results: revenue $3.1 billion, net income $247 million, EPS $2.62.","evidence_excerpt":"and delivering the highest standard of care for our patients.\" Financial and operating highlights for the quarter ended September 30, 2023: • Consolidated revenues were $3.1 billion. • Operating income was $496 million and adjusted operating income was $525 million. • Diluted earnings per share was $2.62 and adjusted diluted earnings per share was $2.85. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000207/0000927066-23-000207-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$3.1 billion"},{"label":"Net income","value":"$247 million"},{"label":"EPS","value":"$2.62"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}